MIL OSI Translation. Region: Germany / Deutschland –
Source: BMW Group Munich. In the first three months of this year, the BMW Group delivered 636,606 vehicles of the BMW, MINI and Rolls-Royce brands (+ 33.5%) and thus achieved a new record in the first quarter. Between January and March, the company was able to increase sales in all major regions of the world compared to the previous year, and all group brands worldwide achieved sales growth in this period.
“We continued our growth path in the first quarter of this year and sold more vehicles than ever before in this period. This record sales underscores our ambitious growth targets for this year, ”said Pieter Nota, Member of the Board of Management of BMW AG, responsible for customers, brands and sales. “Above all, the great demand for our electrified vehicles has spurred sales. In the past three months, we have sold more than twice as many electric vehicles as in the same period of the previous year. We are on course to
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Frontier Announces Pricing of Initial Public Offering
Frontier Airlines, Inc.April 1, 2021 GMT
DENVER, March 31, 2021 (GLOBE NEWSWIRE) Frontier Group Holdings, Inc. (“Frontier”) today announced the pricing of its initial public offering of 30 million shares of its common stock at a price to the public of $19.00 per share. The offering consists of 15 million shares of common stock offered by Frontier and 15 million shares of common stock to be sold by certain of Frontier’s existing stockholders. A selling stockholder has granted the underwriters a 30-day option to buy an additional 4.5 million shares of common stock from such selling stockholder at the initial public offering price, less the underwriting discount and commissions. Frontier will receive net proceeds of approximately $266 million after deducting the underwriting discount and commissions and estimated offering expense
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults
January 29, 2021 12:20 ET | Source: Arvelle Therapeutics Arvelle Therapeutics
Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate
When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom
ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of cenobamate for the